Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C48402
http://purl.obolibrary.org/obo/NCIT_C48402
|
|---|---|
| Preferred Name | Lestaurtinib |
| Definitions |
An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. (NCI05)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. (NCI05) |
|---|---|
| prefLabel | Lestaurtinib
|
| label | Lestaurtinib
|
| PDQ_Closed_Trial_Search_ID | 367053
|
| code | C48402
|
| Has_Target | |
| prefixIRI | NCIT:C48402
|
| in_subset |
See more
See less
|
| Display_Name | Lestaurtinib
|
| Preferred_Name | Lestaurtinib
|
| FDA_UNII_Code | DO989GC5D1
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C26H21N3O4
|
| Maps_To | Lestaurtinib
|
| CAS_Registry | 111358-88-4
|
| NCI_Drug_Dictionary_ID | 367053
|
| Legacy Concept Name | Lestaurtinib
|
| type | |
| ALT_DEFINITION | A drug being studied in the treatment of acute leukemias and some other types of cancer. It binds to a protein that is present on the surface of some types of cancer cells and stops them from dividing. CEP-701 is a type of receptor tyrosine kinase inhibitor and a type of indolocarbazole alkaloid.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 367053
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1541677
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |